The announcement of a class action lawsuit against Kyverna Therapeutics is likely to negatively impact its stock price in the short term as it raises concerns about potential financial liabilities and investor sentiment. The high relevance and importance are due to the direct impact on the company's legal standing and potential financial outcomes.